Group addressed what we believe are inaccurate and misleading claims made in a short-seller report issued by Scorpion ...

Shares of organ transplant innovator TransMedics Group (NASDAQ: TMDX) fell 15.7% through Thursday trading, according to data ...

TransMedics is facing allegations of fraud, organ trafficking, and unethical practices that have triggered shareholder ...

Scorpion Capital accuses TransMedics of fraudulent practices, kickbacks, and racketeering, setting a price target of $0.00. TransMedics denies the claims, stating the allegations aim to manipulate ...

Scorpion Capital has assigned a target price of $0 to TransMedics stock, suggesting the firm believes the company’s alleged misconduct poses an existential threat. Hagens Berman’s ...

NDAQ:TMDX) The Schall Law Firm Invites Investors With Losses To Join An Inquiry Into TransMedics Group, Inc. For Securities Fraud ...

We maintain cautious stance on TransMedics investment due to high-risk factors. Read here for an analysis of TMDX stock drop and future prospects.

What is this about: On January 10, 2025, Scorpion Capital issued a report about TransMedics. In this report, Scorpion Capital stated that in “20 years of shorting, TransMedics is the most extreme and ...

TransMedics has had a tough stretch of late. Last Friday, short-seller Scorpion Capital published a short report on the company. Management vehemently denied wrongdoing, and said it was exploring ...

Last Friday, Scorpion Capital published a 342-page short report -- yes, 342 pages! -- detailing an alleged six-month investigation into TransMedics and its business practices. TransMedics has ...